CJC-1295 + Ipamorelin: Mechanism, Evidence, and Dosing Protocols

Research disclaimer: CJC-1295 and Ipamorelin are sold for research purposes only and are not intended for human consumption. The information below is drawn from published scientific literature.

Evidence Tier

Human clinical trial data for both compounds individually. Phase II data for CJC-1295; human safety and efficacy studies for Ipamorelin. The combination has pharmacological synergy documented in research. Among the better-evidenced stacks in the peptide literature.

Both compounds have been through structured clinical evaluation. CJC-1295 (with DAC) was taken through Phase I/II trials by ConjuChem. Ipamorelin was developed by Novo Nordisk and evaluated in multiple clinical studies including a Phase IIb trial for post-operative ileus. Human GH and IGF-1 elevation data exists for both compounds.

What Are These Compounds?

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the 44-amino acid peptide that signals the pituitary to release growth hormone. Native GHRH has a plasma half-life of only 6–7 minutes, limited by DPP-IV enzyme cleavage and other degradation pathways. CJC-1295 addresses this through two modifications:

1. Amino acid substitutions at positions 2, 8, 15, and 27 that prevent DPP-IV cleavage and other degradation
2. Drug Affinity Complex (DAC) — a maleimidoproprionic acid reactive group that covalently bonds to circulating albumin, extending half-life from minutes to 6–8 days

The no-DAC version (Mod-GRF 1-29, also called CJC-1295 without DAC) lacks the albumin-binding group and has a half-life of approximately 30 minutes — much shorter but produces a sharper, more pulsatile GH release more similar to natural GHRH physiology.

CJC-1295 data page

Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed as a selective ghrelin receptor (GHS-R1a) agonist. It was designed to produce GH secretion via the ghrelin pathway — a completely separate receptor system from GHRH — while avoiding the cortisol, prolactin, and ACTH elevation seen with earlier GH secretagogues like GHRP-2 and GHRP-6.

The selectivity of Ipamorelin for the GHS-R1a receptor, with minimal activity at other ghrelin-family receptors, is its key pharmacological differentiator. Phase IIb clinical trials confirmed the human GH-secreting activity and the absence of significant cortisol/prolactin elevation.

Ipamorelin data page

Mechanism of Action

The Dual-Receptor System

GH secretion from pituitary somatotrophs is regulated by two competing signals: GHRH stimulates release; somatostatin inhibits it. Natural GH pulses occur when GHRH surges and somatostatin is suppressed — primarily during the first 2–3 hours of slow-wave sleep.

CJC-1295 (GHRH receptor) and Ipamorelin (ghrelin receptor) activate two distinct receptor systems on the same pituitary cells. The intracellular pathways converge:

• GHRH receptor → cAMP → PKA → GH secretion
• Ghrelin receptor → phospholipase C → IP3/DAG → calcium mobilisation → GH secretion

When both pathways are activated simultaneously, the GH pulse produced is superadditive — larger than the sum of each compound’s individual effect. This is one of the few peptide combinations where true mechanistic synergy (rather than mere additive effect) is demonstrated.

DAC vs No-DAC: Which to Use

Most current researcher protocols use no-DAC (Mod-GRF 1-29) to produce a sharper GH pulse before sleep, which better mimics natural GH physiology. The DAC version, while convenient (weekly dosing), maintains a chronically elevated GHRH signal that may reduce the pulsatile nature of GH release.

What the Evidence Actually Shows

CJC-1295 (with DAC) — Human Data

ConjuChem’s Phase I/II trials (published 2006, JCEM): Single and multiple doses of CJC-1295 in healthy adults produced dose-dependent increases in GH (2–10× baseline) and IGF-1 (1.5–3× baseline) that persisted for 6+ days. Safety profile was acceptable. This is clean, peer-reviewed human data.

Ipamorelin — Human Data

Ipamorelin has been studied in multiple Phase I and Phase II trials. GH elevation after single dose was 3–6× baseline. The critical finding: cortisol and ACTH were not significantly elevated at effective GH-stimulating doses — confirming the selectivity claim. Post-operative ileus Phase IIb trial (Elixir Medical) showed safety; efficacy data was mixed for the bowel indication.

Body Composition

Human data on body composition from GH secretagogues is modest. GH elevation in the normal-to-high physiological range (which is what secretagogues produce) results in measurable but small changes in lean mass and fat mass over months. These are not the dramatic changes seen with supraphysiological exogenous GH. The changes are real but require realistic expectations.

Sleep Quality

GHRH and GH are tightly linked to slow-wave sleep. Multiple studies show that GHRH administration (and, by extension, GHRH analogs) improves sleep architecture — increasing slow-wave sleep depth and duration. This is a consistent and mechanistically coherent finding.

What Is Not Established

• Long-term effects of chronic pituitary GHRH receptor stimulation
• Whether the no-DAC version produces the same systemic IGF-1 elevation as the DAC version
• Optimal cycle length and off-period requirements for receptor resensitisation
• Effects in individuals with pituitary dysfunction or prior GH axis exposure

Dosing Protocols (Research Context)

Preferred Protocol: No-DAC (Mod-GRF 1-29) + Ipamorelin

Food interaction is critical: Elevated insulin from a recent meal blunts GH release by approximately 40–60%. Fasted administration is not optional — it is the primary protocol variable.

Alternative Protocol: DAC Version

Reconstitution

CJC-1295 no-DAC: For a 2 mg vial + 1 mL bacteriostatic water → 2,000 µg/mL. 100 µg = 0.05 mL = 5 units on U-100 syringe.

Ipamorelin: For a 5 mg vial + 2.5 mL bacteriostatic water → 2,000 µg/mL. 200 µg = 0.1 mL = 10 units on U-100 syringe.

Storage: Lyophilised: −20°C. Reconstituted: refrigerate 2–8°C, use within 30 days. CJC-1295 DAC with albumin-bound complex is somewhat more stable than no-DAC.

Cycle: 8–12 weeks on, 4+ weeks off. There is no RCT data on cycling requirements; the off-period is based on theoretical receptor resensitisation concerns.

Summary

CJC-1295 and Ipamorelin are the best-characterised GH secretagogue combination in the research peptide literature, with human trial data for both compounds individually and documented mechanistic synergy via dual-receptor activation. The clinical evidence shows real GH and IGF-1 elevation in humans. The body composition effects are real but modest compared to exogenous GH. The pre-sleep protocol with fasted administration is the critical variable — without it, the GH pulse is substantially attenuated. For researchers interested in GH axis optimisation through physiological mechanisms rather than supraphysiological exogenous GH exposure, this is where the evidence supports working.

See also: CJC-1295 data page · Ipamorelin data page · GH Optimisation Stack guide